Videos

Post-CDK4/6 Progression in HR+/HER2- mBC: What's Next?

Part 1: Continuing CDK4/6 inhibition and oral endocrine therapies

What are your options when HR+/HER2-negative metastatic breast cancer progresses on a CDK4/6 inhibitor? Prof. Wendy Chan (The University of Hong Kong) reviews the evidence on continuing CDK4/6 inhibition beyond progression. She also covers oral endocrine therapies for ESR1-mutated disease, including early switching guided by ctDNA monitoring, and the practical points of administration, adverse events, and monitoring.

  • 0:00 Introduction and first-line CDK4/6 inhibitor therapy
  • 1:18 Treatment strategies after CDK4/6 progression
  • 1:50 Continuing CDK4/6 inhibition: MAINTAIN, postMONARCH, PALMIRA
  • 3:56 Oral endocrine therapies in ESR1-mutated disease: EMERALD, EMBER-3, VERITAC-2
  • 5:18 ctDNA-guided early switching: SERENA-6
  • 6:01 Administration, adverse events, and monitoring

Part 2: Targeting the PI3K/AKT pathway

Up to half of patients with HR+/HER2-negative breast cancer have alterations in the PI3K/AKT/PTEN pathway. Prof. Chan walks through the pivotal trials for alpelisib, capivasertib, and inavolisib. She explains when to follow a negative liquid biopsy with tissue testing and compares the toxicity profiles you’ll need to manage in practice.

  • 0:00 PI3K/AKT/PTEN pathway alterations
  • 0:25 Alpelisib: SOLAR-1
  • 1:15 Liquid vs tissue biopsy for PIK3CA testing
  • 3:07 Capivasertib: CAPItello-291
  • 6:03 Inavolisib: INAVO120
  • 8:00 Comparing toxicities: rash and hyperglycemia

Part 3: Beyond endocrine therapy: PARP inhibitors and ADCs

When endocrine-based options run out, biomarkers guide what comes next. Prof. Chan covers PARP inhibitors for germline BRCA mutations and how the HER2 spectrum, including HER2-low and HER2-ultralow, opens the door to antibody-drug conjugates (ADCs). She closes with a practical approach to biomarker testing and a summary of post-CDK4/6 options.

  • 0:00 Germline BRCA mutations and PARP inhibitors: OlympiAD, EMBRACA
  • 1:43 The HER2 spectrum and trastuzumab deruxtecan: DESTINY-Breast04, DESTINY-Breast06
  • 3:28 Sacituzumab govitecan: TROPiCS-02
  • 4:41 Datopotamab deruxtecan: TROPION-Breast01
  • 5:09 Biomarker testing: liquid and tissue biopsy, NGS
  • 5:47 Summary and key takeaways

How would you rate this content?

This site is only for use by healthcare professionals.
By continuing to view this site you are confirming that you are a healthcare professional.

Confirm